1. Academic Validation
  2. Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A2A Adenosine Receptor Antagonists

Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A2A Adenosine Receptor Antagonists

  • J Med Chem. 2025 Aug 14;68(15):16802-16818. doi: 10.1021/acs.jmedchem.5c01774.
Gibae Kim 1 2 Seung Woo Kim 1 Hongseok Choi 1 Ji Yong Kim 3 Sang Yeop Ahn 3 Jong Hyun Lee 4 Jae-Eon Lee 5 Yong Hyun Jeon 5 Lak Shin Jeong 1 3
Affiliations

Affiliations

  • 1 Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
  • 2 Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
  • 3 Future Medicine Co. Ltd, 54 Changup-ro, Sujeong-gu, Seongnam, Gyeonggi-do 13449, Republic of Korea.
  • 4 HK inno.N Corp., Seoul 04551, Republic of Korea.
  • 5 Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
Abstract

Previous molecular dynamics simulations of hA2AAR with 2b and structure-activity relationship (SAR) analyses prompted us to synthesize diol-, deoxy-, fluoro-, and methoxy-derivatives (4) in a regio- and stereoselective manner, modifying the ribose moiety to enhance potency and selectivity at hA2AAR. SAR analysis revealed that the presence of at least one hydroxyl group at either the R2 or R4 position is preferred for hA2AAR binding, and inversion of the R4 hydroxyl group significantly reduced binding affinity at hA3AR. Alteration of the hydroxyl groups in the ribose moiety showed that hA3AR favored diol derivatives, and the following trend was observed at hA2AAR: Ki,hA2A, diol ≈ deoxy < fluoro < methoxy. Among the synthesized derivatives, the deoxy derivative 4d demonstrated exceptional in vitro potency at hA2AAR (Ki,hA2A = 0.36 ± 0.05 nM) and functional efficacy. Additionally, 4d exhibited promising pharmacokinetic properties, and in vivo efficacy assays confirmed its potential as an orally available immune checkpoint inhibitor candidate.

Figures
Products